4-ethyl-3,5-dimethyl-1-phenyl-1H-pyrazole | 91821-00-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-ethyl-3,5-dimethyl-1-phenyl-1H-pyrazole
• 英文别名: 3,5-Dimethyl-4-ethyl-1-phenyl-pyrazol；4-Ethyl-3,5-dimethyl-1-phenylpyrazole
• CAS: 91821-00-0
• 化学式: C₁₃H₁₆N₂
• mdl: MFCD14587108
• 分子量: 200.283
• InChiKey: CBZUJIMWROQAII-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.307
• 拓扑面积：
  17.8
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  3-乙基-2,4-戊二酮 、 苯肼 在 nickel(II) chloride hexahydrate 作用下， 以 水 为溶剂， 反应 4.0h， 以60%的产率得到4-ethyl-3,5-dimethyl-1-phenyl-1H-pyrazole
  参考文献：
  名称：

  氯化镍催化室温下肼合成吡唑和 phthalazin-1(2H)-ones

  摘要：

  本文开发了一种有效且简单的方案，用于从氯化镍催化的常见前体肼合成吡唑和 phthalazin-1(2H)-ones。反应在室温下在水中进行。该协议的优点是，两种重要的药用支架都可以用低成本催化剂、绿色溶剂、相对较短的反应时间和较高的产品产量合成，使该协议在综合上非常有用。电子多样化的吡唑和酞嗪酮可以在相对较短的反应时间内以良好至优异的产率获得。

  DOI：

  10.1016/j.tetlet.2022.153842

文献信息

• Efficient Copper-Catalyzed Synthesis of Substituted Pyrazoles at Room Temperature
  作者：Haifeng Wang、Xiangli Sun、Shuangling Zhang、Guanglu Liu、Chunjie Wang、Lili Zhu、Hui Zhang

  DOI：10.1055/s-0037-1610330

  日期：2018.12

  method for the synthesis of pyrazoles through a copper-catalyzed condensation reaction has been developed. The new catalytic system not only maintained a broad substrate scope but was also active under acid-free reaction conditions, overcoming the conventional requirement for an acid-catalyzed system. Furthermore, the copper catalyst enabled this reaction to be performed at room temperature and in a short

  已开发出一种通过铜催化缩合反应合成吡唑的有效方法。新的催化体系不仅保持了广泛的底物范围，而且在无酸反应条件下也具有活性，克服了对酸催化体系的传统要求。此外，铜催化剂使该反应能够在室温下和较短的反应时间内进行。
• Magnetic Nanoparticle-Supported Glutathione as a Sustainable Organocatalyst
  申请人：Varma Rajender S.

  公开号：US20110054180A1

  公开（公告）日：2011-03-03

  This invention relates to the use of nano-organocatalysts, and, more specifically, to the use of magnetic nanomaterial-supported organocatalysts. It is an object of the present invention to provide “green” catalysts and protocols. According to one embodiment of the invention, a nano-organocatalyst in the form of a magnetic nanomaterial-supported organocatalyst is provided. According to other embodiments of the invention, glutathione and cysteine are provided as organocatalysts and magnetic nanomaterial-supported glutathione and magnetic nanomaterial-supported cysteine are provided for use as nano-organocatalysts. According to another embodiment of the invention, a method of using a recyclable magnetic nanomaterial-supported organocatalyst using a totally benign aqueous protocol, without using any organic solvent in the reaction or during the workup, is provided. According to a further embodiment of the invention, a recyclable magnetic nanomaterial-supported organocatalyst for various organocatalytic reactions, including but not limited to Paal-Knorr reactions, aza-Michael addition and pyrazole synthesis, is provided.

  本发明涉及纳米有机催化剂的使用，更具体地涉及磁性纳米材料支撑的有机催化剂的使用。本发明的目的是提供“绿色”催化剂和方案。根据本发明的一个实施例，提供了一种磁性纳米材料支撑的有机催化剂的纳米有机催化剂。根据本发明的其他实施例，提供了谷胱甘肽和半胱氨酸作为有机催化剂，以及用作纳米有机催化剂的磁性纳米材料支撑的谷胱甘肽和磁性纳米材料支撑的半胱氨酸。根据本发明的另一个实施例，提供了一种使用可回收磁性纳米材料支撑的有机催化剂的方法，使用完全良性的水相方案，在反应过程中或处理过程中不使用任何有机溶剂。根据本发明的另一个实施例，提供了一种用于各种有机催化反应的可回收磁性纳米材料支撑的有机催化剂，包括但不限于Paal-Knorr反应、aza-Michael加成和吡唑合成。
• Piperidine derivatives having ccr3 antagonism
  申请人：Matsumoto Yoshiyuki

  公开号：US20070032525A1

  公开（公告）日：2007-02-08

  The invention provides low molecular compounds having activity which inhibits binding of CCR3 ligands to CCR3 on target cells, i.e. CCR3 antagonists. The invention also provides compounds represented by formula (I) below, pharmaceutically acceptable acid adducts thereof, or pharmaceutically acceptable C 1 -C 6 alkyl adducts thereof, as well as pharmaceutical compositions comprising them as effective ingredients, which are useful for treatment or prevention of diseases associated with CCR3, such as asthma and allergic rhinitis.

  本发明提供了具有抑制CCR3配体结合到靶细胞CCR3的活性的低分子化合物，即CCR3拮抗剂。本发明还提供了由下式（I）表示的化合物，其药学上可接受的酸加合物或药学上可接受的C1-C6烷基加合物，以及包含它们作为有效成分的制药组合物，用于治疗或预防与CCR3相关的疾病，例如哮喘和过敏性鼻炎。
• 4,4-Disubstituted) piperidine derivatives having ccr3 antagonism
  申请人：Matsumoto Yoshiyuki

  公开号：US20070037851A1

  公开（公告）日：2007-02-15

  The invention provides low molecular compounds having activity which inhibits binding of CCR3 ligands to CCR3 on target cells, i.e. CCR3 antagonists. The invention also provides 4,4-(disubstituted)piperidine derivatives represented by formula (I) below, pharmaceutically acceptable acid adducts thereof, or pharmaceutically acceptable C 1 -C 6 alkyl adducts thereof, as well as pharmaceutical compositions comprising them as effective ingredients, which are useful for treatment or prevention of diseases associated with CCR3, such as asthma and allergic rhinitis.

  本发明提供了具有抑制CCR3配体与靶细胞上CCR3结合活性的低分子化合物，即CCR3拮抗剂。本发明还提供了由下式（I）所表示的4,4-(二取代)哌啶衍生物，其药学上可接受的酸加合物或药学上可接受的C1-C6烷基加合物，以及包含它们作为有效成分的药物组合物，用于治疗或预防与CCR3相关的疾病，如哮喘和过敏性鼻炎。
• Nano-organocatalyst: magnetically retrievable ferrite-anchored glutathione for microwave-assisted Paal–Knorr reaction, aza-Michael addition, and pyrazole synthesis
  作者：Vivek Polshettiwar、Rajender S. Varma

  DOI：10.1016/j.tet.2009.11.015

  日期：2010.1

  Postsynthetic Surface modification of magnetic nanoparticles by glutathione imparts desirable chemical functionality and enables the generation of catalytic sites on the surfaces of ensuing organocatalysts. In this article, we discuss the developments, unique activity, and high selectivity of nano-organocatalysts for microwave-assisted Paal-Knorr reaction, aza-Michael addition, and pyrazole synthesis. Their insoluble character Coupled with paramagnetic nature enables easy separation of these nano-catalysts from the reaction mixture using external magnet, which eliminates the requirement of catalyst filtration. Published by Elsevier Ltd.